US patent breakthrough for Sareum
Cambridge drug development business Sareum Holdings plc saw its share price rise more than 13 per cent in the UK after receiving a patent boost in the US.
The AIM-quoted company is delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
In a genuine breakthrough development, Sareum reveals that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme.
This programme is in preclinical development and targets cancer and cancer immunotherapy. The patent will protect the SDC-1802 molecule and pharmaceutical preparations arising from the research.
Subject to certain formalities being completed, the company expects that the patent will be granted within three months.T his will complete the patent protection for this programme across all major territories.
The landmark follows similar patent protection being granted to the company in Europe, Japan and China.
Sareum’s CSO Dr John Reader said: “The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.
“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company’s negotiating position as it continues to engage in discussions with potential licence partners.”